Alterity Therapeutics Limited Share Price Nasdaq
Stocks
ATHE
US02155X2053
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.540 USD | -3.20% |
|
-8.84% | +47.40% |
| Market Cap | 8.52Cr 7.48Cr 6.96Cr 6.38Cr 12Cr 820.27Cr 12Cr 83Cr 32Cr 403.27Cr 32Cr 31Cr 1.39TCr | P/E 2026 * |
-0.33x | P/E 2027 * | -0.33x |
|---|---|---|---|---|---|
| Enterprise Value | 4Cr 3.51Cr 3.27Cr 3Cr 5.63Cr 385.1Cr 5.72Cr 39Cr 15Cr 189.33Cr 15Cr 15Cr 654.61Cr | EV / Sales 2026 * |
15.6x | EV / Sales 2027 * | 36.9x |
| Free-Float |
91.76% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Alterity Therapeutics Limited
| 1 day | -3.20% | ||
| 1 week | -8.84% | ||
| Current month | -15.46% | ||
| 1 month | -10.37% | ||
| 3 months | +2.95% | ||
| 6 months | +27.89% | ||
| Current year | +47.40% |
| 1 week | 4.46 |  | 5 |
| 1 month | 4.46 | | 5.89 |
| Current year | 3.02 | | 5.89 |
| 1 year | 2.66 | | 6.03 |
| 3 years | 1 | | 7 |
| 5 years | 1 | | 18.2 |
| 10 years | 1 | | 66.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 65 | 07/01/2021 |
Abby Niven
DFI | Director of Finance/CFO | - | 30/09/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Marks
BRD | Director/Board Member | 70 | 29/07/2005 |
Lawrence Gozlan
BRD | Director/Board Member | 47 | 08/08/2011 |
David Stamler
BRD | Director/Board Member | 65 | 21/11/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.20% | -8.84% | - | - | 8.52Cr | |
| +1.07% | -3.49% | -3.25% | +12.87% | 4.69TCr | |
| +0.25% | +1.65% | +408.41% | +629.49% | 4.02TCr | |
| -0.27% | +4.45% | +9.93% | +66.92% | 3.62TCr | |
| +0.35% | +0.87% | +3.60% | -8.81% | 3.47TCr | |
| +3.14% | +1.02% | +3.37% | +38.15% | 2.79TCr | |
| -0.73% | +11.84% | +31.97% | +143.53% | 1.68TCr | |
| +0.47% | -2.74% | - | - | 1.67TCr | |
| +0.42% | -5.52% | +0.76% | +8.50% | 1.31TCr | |
| -2.68% | -2.49% | -15.00% | -31.68% | 1.27TCr | |
| Average | -0.12% | +0.83% | +54.97% | +107.37% | 2.73TCr | |
| Weighted average by Cap. | +0.48% | +0.91% | +75.32% | +136.64% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 25.68L 22.56L 20.98L 19.25L 36.17L 25Cr 36.73L 2.49Cr 97.33L 12Cr 96.42L 94.34L 42Cr | 12L 10.54L 10L 9L 16.9L 12Cr 17.16L 1.16Cr 45.48L 5.68Cr 45.06L 44.09L 20Cr |
| Net income | -1.46Cr -1.29Cr -1.2Cr -1.1Cr -2.06Cr -141.02Cr -2.09Cr -14Cr -5.55Cr -69Cr -5.5Cr -5.38Cr -239.71Cr | -2.97Cr -2.61Cr -2.42Cr -2.22Cr -4.18Cr -285.63Cr -4.24Cr -29Cr -11Cr -140.43Cr -11Cr -11Cr -485.53Cr |
| Net Debt | -4.52Cr -3.97Cr -3.69Cr -3.39Cr -6.36Cr -435.17Cr -6.46Cr -44Cr -17Cr -213.94Cr -17Cr -17Cr -739.72Cr | -4.09Cr -3.59Cr -3.34Cr -3.06Cr -5.76Cr -393.69Cr -5.85Cr -40Cr -15Cr -193.55Cr -15Cr -15Cr -669.21Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/26/24 | $4.540 | -3.20% | 17,932 |
| 23/26/23 | $4.690 | -0.21% | 9,553 |
| 22/26/22 | $4.700 | -5.62% | 11,650 |
| 21/26/21 | $4.980 | +5.06% | 2,860 |
| 20/26/20 | $4.740 | -4.82% | 44,197 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ATH Stock
- ATHE Stock
Select your edition
All financial news and data tailored to specific country editions
